18%). Dose-limiting toxicities included thrombocytopenia (19% for hydroxyurea vs. 1% for placebo; difference, 18 percentage points; 95% CI, 9-26), neutropenia (13% vs. 0%; difference, 13 ...

However, hydroxyurea was associated with fewer vaso ... The most common DLTs were thrombocytopenia and neutropenia, both occurring more frequently in adults. Older age, lower platelet count ...

Fewer ED visits per year and fewer hospital days per year seen in association with hydroxyurea use. HealthDay News — For children with sickle cell anemia (SCA), hydroxyurea has sustained ...

Hydroxyurea is an oral chemotherapy drug that doctors may prescribe to people with sickle cell disease. It may help prevent complications due to sickle-shaped blood cells clumping together in ...

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.

Hydroxyurea may falsely elevate sensor glucose results from certain CGM systems. The prescribing information for hydroxyurea has been updated to include information regarding patients who use ...

Of the 2,147 participants, 1,240 (58%) had used hydroxyurea; of those, the average time on hydroxyurea was 5.1 years, with 304 children aged eight or older on continuous hydroxyurea therapy.

Hydroxyurea remains effective over the long term among children with sickle cell disease, real-world data suggested. The average time on hydroxyurea was 5 years, with many children on the therapy ...

While hydroxyurea has had U.S. Food and Drug Administration approval as a sickle cell disease treatment for children since 2017, its accessibility and acceptance in Africa have been comparatively ...